Observation of Treatment Patterns With Lucentis in Approved Indications

CompletedOBSERVATIONAL
Enrollment

5,778

Participants

Timeline

Start Date

December 8, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV
Trial Locations (1)

72076

Novartis Investigative Site, Tübingen

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY